International Clinical Trial: Prospective, Single-Arm, Phase II Clinical Study of Ivonescimab Combined with TROP2 ADC in the Treatment of Brain Metastases from Triple-Negative Breast Cancer

Geneva, Oct. 15 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133876) titled 'Prospective, Single-Arm, Phase II Clinical Study of Ivonescimab Combined with TROP2 ADC in the Treatment of Brain Metastases from Triple-Negative Breast Cancer' on Oct. 9.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Fudan University Shanghai Cancer Center

Condition: triple-negative breast cancer with brain metastases

Recruitment Status: Not Recruiting

Phase: 2

Date of First Enrollment: 2024-12-20

Target Sample Size: experimental group:39;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=334028

Disclaimer: Curated by HT ...